Monitors call early stop to Imbruvica CLL trial

Share this article:

A Phase-III trial of Janssen and Pharmacyclics' Imbruvica (ibrutinib) testing an expanded use for the drug, in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), was stopped early on the recommendation of an Independent Data Monitoring Committee (IDMC). Monitors said the drug had already met its primary endpoint and a key secondary one: statistically significant improvement in progression free survival (PFS) and overall survival (OS).

Janssen and Pharmcyclics—who signed a collaborative agreement in December 2011 to co-develop and market the drug—said data from the trial will be presented at an upcoming oncology conference. Pharmacyclics has informed FDA of this data; Janssen has informed the European Medicines Agency (EMA).

Imbruvica was approved in November for treating mantle cell lymphoma (MCL), after receiving priority review in July of last year. Analysts have said the drug could reach billions in annual sales, owing to its oral formulation and potential to be used without chemo, traits that have drawn comparisons to Novartis's blockbuster leukemia pill Gleevec.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.